225 related articles for article (PubMed ID: 27275474)
1. Prognostic factors for long term survival in patients with advanced non-small cell lung cancer.
Moumtzi D; Lampaki S; Zarogoulidis P; Porpodis K; Lagoudi K; Hohenforst-Schmidt W; Pataka A; Tsiouda T; Zissimopoulos A; Lazaridis G; Karavasilis V; Timotheadou H; Barbetakis N; Pavlidis P; Kontakiotis T; Zarogoulidis K
Ann Transl Med; 2016 May; 4(9):161. PubMed ID: 27275474
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival analysis of patients with stage IIIB-IV non-small cell lung cancer complicated by type 2 diabetes mellitus: A retrospective propensity score matching analysis.
Li X; Fang H; Zhang D; Xia L; Wang X; Yang J; Zhang S; Su Y; Zhu Y
Thorac Cancer; 2022 Dec; 13(23):3268-3273. PubMed ID: 36217741
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
[TBL] [Abstract][Full Text] [Related]
7. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy.
Bala S; Gundeti S; Linga VG; Maddali LS; Digumarti RR; Uppin SG
Indian J Med Paediatr Oncol; 2016; 37(4):242-250. PubMed ID: 28144090
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution.
Inal A; Kaplan MA; Kucukoner M; Urakci Z; Karakus A; Isikdogan A
Asian Pac J Cancer Prev; 2012; 13(4):1281-4. PubMed ID: 22799319
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia.
Risteski M; Crvenkova S; Atanasov Z; Isjanovska R
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(3):49-61. PubMed ID: 24566015
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
Vasile E; Tibaldi C; Leon GL; D'Incecco A; Giovannetti E
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1189-94. PubMed ID: 25504507
[TBL] [Abstract][Full Text] [Related]
13. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
14. Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: Analysis of the Radiation Therapy Oncology Group experience.
Machtay M; Seiferheld W; Komaki R; Cox JD; Sause WT; Byhardt RW
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):847-53. PubMed ID: 10386642
[TBL] [Abstract][Full Text] [Related]
15. Real-world Prognostic Data on Unresectable Stage III Non-small-cell Lung Cancer Treated with Concurrent Chemoradiation Therapy by Histological Type.
Toriyama K; Yomota M; Asai M; Hashimoto K; Mirokuji K; Kawai S; Watanabe K; Narita K; Hosomi Y
Intern Med; 2024 Feb; ():. PubMed ID: 38346736
[TBL] [Abstract][Full Text] [Related]
16. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
Inal A; Kaplan MA; Kucukoner M; Urakcı Z; Kılınc F; Isıkdogan A
Rev Port Pneumol; 2014; 20(2):62-8. PubMed ID: 24210228
[TBL] [Abstract][Full Text] [Related]
17. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
18. [Exploration of the rational therapeutic regimen for advanced lung cancer patients with mild tumor enlargement].
Zhang XL; Wang XY; Zhang CC; Yang J; Yuan XH; Li K
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):775-782. PubMed ID: 29061023
[No Abstract] [Full Text] [Related]
19. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for survival in a Chinese population presenting with advanced non-small cell lung cancer with an emphasis on smoking status: A regional, single-institution, retrospective analysis of 4552 patients.
Hu Q; Li B; Garfield D; Ren S; Li A; Chen X; Zhou C
Thorac Cancer; 2012 May; 3(2):162-168. PubMed ID: 28920299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
